Cargando…

Does directly observed therapy (DOT) reduce drug resistant tuberculosis?

BACKGROUND: Directly observed therapy (DOT) is a widely recommended and promoted strategy to manage tuberculosis (TB), however, there is still disagreement about the role of DOT in TB control and the impact it has on reducing the acquisition and transmission of drug resistant TB. This study compares...

Descripción completa

Detalles Bibliográficos
Autores principales: Moonan, Patrick K, Quitugua, Teresa N, Pogoda, Janice M, Woo, Gary, Drewyer, Gerry, Sahbazian, Behzad, Dunbar, Denise, Jost, Kenneth C, Wallace, Charles, Weis, Stephen E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032680/
https://www.ncbi.nlm.nih.gov/pubmed/21214913
http://dx.doi.org/10.1186/1471-2458-11-19
_version_ 1782197481261498368
author Moonan, Patrick K
Quitugua, Teresa N
Pogoda, Janice M
Woo, Gary
Drewyer, Gerry
Sahbazian, Behzad
Dunbar, Denise
Jost, Kenneth C
Wallace, Charles
Weis, Stephen E
author_facet Moonan, Patrick K
Quitugua, Teresa N
Pogoda, Janice M
Woo, Gary
Drewyer, Gerry
Sahbazian, Behzad
Dunbar, Denise
Jost, Kenneth C
Wallace, Charles
Weis, Stephen E
author_sort Moonan, Patrick K
collection PubMed
description BACKGROUND: Directly observed therapy (DOT) is a widely recommended and promoted strategy to manage tuberculosis (TB), however, there is still disagreement about the role of DOT in TB control and the impact it has on reducing the acquisition and transmission of drug resistant TB. This study compares the portion of drug resistant genotype clusters, representing recent transmission, within and between communities implementing programs differing only in their directly observed therapy (DOT) practices. METHODS: Genotype clusters were defined as 2 or more patient members with matching IS6110 restriction fragment length polymorphism (RFLP) and spoligotype patterns from all culture-positive tuberculosis cases diagnosed between January 1, 1995 and December 31, 2001. Logistic regression was used to compute maximum-likelihood estimates of odds ratios (ORs) and 95% confidence intervals (CIs) comparing cluster members with and without drug resistant isolates. In the universal DOT county, all patients received doses under direct observation of health department staff; whereas in selective DOT county, the majority of received patients doses under direct observation of health department staff, while some were able to self-administer doses. RESULTS: Isolates from 1,706 persons collected during 1,721 episodes of tuberculosis were genotyped. Cluster members from the selective DOT county were more than twice as likely than cluster members from the universal DOT county to have at least one isolate resistant to isoniazid, rifampin, and/or ethambutol (OR = 2.3, 95% CI: 1.7, 3.1). Selective DOT county isolates were nearly 5 times more likely than universal DOT county isolates to belong to clusters with at least 2 resistant isolates having identical resistance patterns (OR = 4.7, 95% CI: 2.9, 7.6). CONCLUSIONS: Universal DOT for tuberculosis is associated with a decrease in the acquisition and transmission of resistant tuberculosis.
format Text
id pubmed-3032680
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30326802011-02-03 Does directly observed therapy (DOT) reduce drug resistant tuberculosis? Moonan, Patrick K Quitugua, Teresa N Pogoda, Janice M Woo, Gary Drewyer, Gerry Sahbazian, Behzad Dunbar, Denise Jost, Kenneth C Wallace, Charles Weis, Stephen E BMC Public Health Research Article BACKGROUND: Directly observed therapy (DOT) is a widely recommended and promoted strategy to manage tuberculosis (TB), however, there is still disagreement about the role of DOT in TB control and the impact it has on reducing the acquisition and transmission of drug resistant TB. This study compares the portion of drug resistant genotype clusters, representing recent transmission, within and between communities implementing programs differing only in their directly observed therapy (DOT) practices. METHODS: Genotype clusters were defined as 2 or more patient members with matching IS6110 restriction fragment length polymorphism (RFLP) and spoligotype patterns from all culture-positive tuberculosis cases diagnosed between January 1, 1995 and December 31, 2001. Logistic regression was used to compute maximum-likelihood estimates of odds ratios (ORs) and 95% confidence intervals (CIs) comparing cluster members with and without drug resistant isolates. In the universal DOT county, all patients received doses under direct observation of health department staff; whereas in selective DOT county, the majority of received patients doses under direct observation of health department staff, while some were able to self-administer doses. RESULTS: Isolates from 1,706 persons collected during 1,721 episodes of tuberculosis were genotyped. Cluster members from the selective DOT county were more than twice as likely than cluster members from the universal DOT county to have at least one isolate resistant to isoniazid, rifampin, and/or ethambutol (OR = 2.3, 95% CI: 1.7, 3.1). Selective DOT county isolates were nearly 5 times more likely than universal DOT county isolates to belong to clusters with at least 2 resistant isolates having identical resistance patterns (OR = 4.7, 95% CI: 2.9, 7.6). CONCLUSIONS: Universal DOT for tuberculosis is associated with a decrease in the acquisition and transmission of resistant tuberculosis. BioMed Central 2011-01-07 /pmc/articles/PMC3032680/ /pubmed/21214913 http://dx.doi.org/10.1186/1471-2458-11-19 Text en Copyright ©2011 Moonan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Moonan, Patrick K
Quitugua, Teresa N
Pogoda, Janice M
Woo, Gary
Drewyer, Gerry
Sahbazian, Behzad
Dunbar, Denise
Jost, Kenneth C
Wallace, Charles
Weis, Stephen E
Does directly observed therapy (DOT) reduce drug resistant tuberculosis?
title Does directly observed therapy (DOT) reduce drug resistant tuberculosis?
title_full Does directly observed therapy (DOT) reduce drug resistant tuberculosis?
title_fullStr Does directly observed therapy (DOT) reduce drug resistant tuberculosis?
title_full_unstemmed Does directly observed therapy (DOT) reduce drug resistant tuberculosis?
title_short Does directly observed therapy (DOT) reduce drug resistant tuberculosis?
title_sort does directly observed therapy (dot) reduce drug resistant tuberculosis?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032680/
https://www.ncbi.nlm.nih.gov/pubmed/21214913
http://dx.doi.org/10.1186/1471-2458-11-19
work_keys_str_mv AT moonanpatrickk doesdirectlyobservedtherapydotreducedrugresistanttuberculosis
AT quituguateresan doesdirectlyobservedtherapydotreducedrugresistanttuberculosis
AT pogodajanicem doesdirectlyobservedtherapydotreducedrugresistanttuberculosis
AT woogary doesdirectlyobservedtherapydotreducedrugresistanttuberculosis
AT drewyergerry doesdirectlyobservedtherapydotreducedrugresistanttuberculosis
AT sahbazianbehzad doesdirectlyobservedtherapydotreducedrugresistanttuberculosis
AT dunbardenise doesdirectlyobservedtherapydotreducedrugresistanttuberculosis
AT jostkennethc doesdirectlyobservedtherapydotreducedrugresistanttuberculosis
AT wallacecharles doesdirectlyobservedtherapydotreducedrugresistanttuberculosis
AT weisstephene doesdirectlyobservedtherapydotreducedrugresistanttuberculosis